NASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free DYN Stock Alerts $23.69 -1.29 (-5.16%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$23.16▼$24.4850-Day Range$22.41▼$29.1852-Week Range$6.40▼$30.27Volume705,850 shsAverage Volume1.96 million shsMarket Capitalization$2.04 billionP/E RatioN/ADividend YieldN/APrice Target$37.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Dyne Therapeutics alerts: Email Address Dyne Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside58.0% Upside$37.43 Price TargetShort InterestBearish10.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 3 Articles This WeekInsider TradingSelling Shares$44.69 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.25) to ($3.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.21 out of 5 starsMedical Sector299th out of 907 stocksPharmaceutical Preparations Industry129th out of 422 stocks 4.6 Analyst's Opinion Consensus RatingDyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDyne Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.47% of the outstanding shares of Dyne Therapeutics have been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Dyne Therapeutics has recently increased by 11.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DYN. Previous Next 1.2 News and Social Media Coverage News SentimentDyne Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Dyne Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $44,687,450.00 in company stock.Percentage Held by Insiders20.77% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.25) to ($3.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 15.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Dyne Therapeutics Stock (NASDAQ:DYN)Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Read More DYN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DYN Stock News HeadlinesApril 24, 2024 | americanbankingnews.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from BrokeragesApril 22, 2024 | finanznachrichten.deSynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCTApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 16, 2024 | americanbankingnews.comDyne Therapeutics, Inc. (NASDAQ:DYN) Sees Large Increase in Short InterestApril 8, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)March 27, 2024 | globenewswire.comDyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerMarch 27, 2024 | globenewswire.comDyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy SymposiumMarch 26, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Dyne Therapeutics (DYN), Addus Homecare (ADUS)April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 25, 2024 | bizjournals.comDyne announces CEO transition, former Biogen exec tapped for top spotMarch 25, 2024 | marketwatch.comDyne Therapeutics Shares Drop 14% on CEO Joshua Brumm DepartureMarch 25, 2024 | finanznachrichten.deDyne Therapeutics, Inc.: Dyne Therapeutics Announces CEO TransitionMarch 25, 2024 | markets.businessinsider.comDyne Therapeutics Appoints John Cox As CEO To Succeed Joshua BrummMarch 25, 2024 | marketwatch.comDyne Therapeutics CEO Joshua Brumm to Exit For Investing CareerMarch 25, 2024 | globenewswire.comDyne Therapeutics Announces CEO TransitionMarch 20, 2024 | fool.comDyne Therapeutics (NASDAQ: DYN)March 18, 2024 | finance.yahoo.comDYN Apr 2024 30.000 putMarch 16, 2024 | finance.yahoo.comDYN Apr 2024 22.500 callMarch 16, 2024 | ca.finance.yahoo.comDYN Apr 2024 30.000 callMarch 14, 2024 | markets.businessinsider.comNeuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock SurgeMarch 13, 2024 | globenewswire.comDyne Therapeutics to Present at Stifel 2024 Virtual CNS DaysMarch 8, 2024 | markets.businessinsider.comChardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To KnowMarch 7, 2024 | investing.comDyne Therapeutics stock target raised to $41 by StifelMarch 7, 2024 | investing.comDyne Therapeutics stock target raised to $47 on promising dataMarch 7, 2024 | finance.yahoo.comDyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ...March 6, 2024 | markets.businessinsider.comPiper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To KnowMarch 6, 2024 | markets.businessinsider.comDyne Therapeutics: Strong Buy on Promising Clinical Data and Superior Therapeutic PlatformSee More Headlines Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CUSIPN/A CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees141Year FoundedN/APrice Target and Rating Average Stock Price Target$37.43 High Stock Price Target$56.00 Low Stock Price Target$22.00 Potential Upside/Downside+60.3%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-235,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-136.35% Return on Assets-103.67% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book15.67Miscellaneous Outstanding Shares86,180,000Free Float68,279,000Market Cap$2.01 billion OptionableOptionable Beta0.95 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMs. Susanna Gatti High M.B.A. (Age 56)Chief Operating Officer Comp: $754.1kDr. Jonathan McNeill M.D. (Age 39)Chief Business Officer Comp: $662.34kMr. John G. Cox M.B.A. (Age 61)CEO, President & Director Dr. Romesh Subramanian Ph.D. (Age 59)Co-Founder & Advisor Comp: $565.17kMr. Richard William Scalzo M.B.A. (Age 38)Senior VP and Head of Finance & Administration Mr. John Najim M.B.A.Chief Technical OfficerDr. Oxana Beskrovnaya Ph.D. (Age 63)Chief Scientific Officer Comp: $631.08kMs. Amy Reilly (Age 50)Senior VP and Head of Corporate Communications & Investor Relations Mr. Daniel Wilson (Age 52)Senior VP & Head of Legal Ms. Kate MitchellVP & Head of Human ResourcesMore ExecutivesKey CompetitorsTG TherapeuticsNASDAQ:TGTXRocket PharmaceuticalsNASDAQ:RCKTVera TherapeuticsNASDAQ:VERAArvinasNASDAQ:ARVNKeros TherapeuticsNASDAQ:KROSView All CompetitorsInsiders & InstitutionsArcadia Investment Management Corp MIBought 31,325 shares on 4/23/2024Ownership: 0.036%Wetzel Investment Advisors Inc.Bought 1,000 shares on 4/23/2024Ownership: 0.001%Vivo Capital LLCBought 600,000 shares on 4/22/2024Ownership: 1.897%Raymond James & AssociatesBought 82,466 shares on 4/22/2024Ownership: 0.196%Allspring Global Investments Holdings LLCSold 1,108 shares on 4/18/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions DYN Stock Analysis - Frequently Asked Questions Should I buy or sell Dyne Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares. View DYN analyst ratings or view top-rated stocks. What is Dyne Therapeutics' stock price target for 2024? 7 brokers have issued 1 year target prices for Dyne Therapeutics' shares. Their DYN share price targets range from $22.00 to $56.00. On average, they predict the company's stock price to reach $37.43 in the next twelve months. This suggests a possible upside of 58.0% from the stock's current price. View analysts price targets for DYN or view top-rated stocks among Wall Street analysts. How have DYN shares performed in 2024? Dyne Therapeutics' stock was trading at $13.30 on January 1st, 2024. Since then, DYN stock has increased by 78.1% and is now trading at $23.69. View the best growth stocks for 2024 here. Are investors shorting Dyne Therapeutics? Dyne Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 9,020,000 shares, an increase of 11.6% from the March 31st total of 8,080,000 shares. Based on an average daily volume of 1,380,000 shares, the short-interest ratio is currently 6.5 days. View Dyne Therapeutics' Short Interest. When is Dyne Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our DYN earnings forecast. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) announced its earnings results on Tuesday, March, 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.92) by $0.17. What ETFs hold Dyne Therapeutics' stock? ETFs with the largest weight of Dyne Therapeutics (NASDAQ:DYN) stock in their portfolio include Morningstar US Small Growth (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Goldman Sachs Future Health Care Equity ETF (GDOC).iShares Micro-Cap ETF (IWC). When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (1.90%), Wasatch Advisors LP (0.48%), Vida Ventures Advisors LLC (0.47%), Raymond James & Associates (0.20%), Arcadia Investment Management Corp MI (0.04%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Dirk Kersten, Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Oxana Beskrovnaya, Richard William Scalzo, Susanna Gatti High, Venture Fund Xi LP Atlas and Wildon Farwell. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DYN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
